Ceragenix Pharmaceuticals has entered into an exclusive evaluation and option to license agreement with a healthcare company covering the use of the company’s Cerashield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.
Neither the name of the company nor the precise area of interest has been disclosed.
Under the terms of the agreement, the company will have an exclusive period to evaluate, negotiate commercialisation terms and license the specified product application for a period of up to seven months.
Steven Porter, chairman and CEO of Ceragenix, a medical device company focused on infectious disease and dermatology, said this is company’s second development agreement involving its CeraShield antimicrobial coating technology.
In March this year, National Institutes of Health had awarded a $1.66 million grant to the University of Utah to fund research evaluating a Cerashield coating to reduce orthopedic implant infections.
In another development, Ceragenix has entered into an exclusive distribution and supply agreement with Dávi II – Farmacêutica S.A., a Portuguese company, to commercialise EpiCeram, a topical cream for treating atopic dermatitis and other dry skin conditions in Europe.
The agreement grants Dávi exclusivity in the territory for the distribution and marketing of EpiCeram via its own sales force as well as through partnering arrangements. Ceragenix will be responsible for the manufacturing and supply of the product. Dávi is also responsible for obtaining regulatory clearance to market EpiCeram in the territory.
